Navigation Links
Combining medication and psychosocial treatments may benefit patients with early-stage schizophrenia

Patients with early-stage schizophrenia who receive a combination of medication and a psychosocial intervention appear less likely to discontinue treatment or relapseand may have improved insight, quality of life and social functioningthan those taking medication alone, according to a report in the September issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

Antipsychotic drugs are the mainstay of therapy for patients with schizophrenia, but long-term therapy is associated with adverse effects and poor adherence, according to background information in the article. "Most patients, even those with a good response to medication, continue to experience disabling residual symptoms, impaired social and occupational functioning and a high rate of relapse," the authors write. "Adding psychosocial treatment may produce greater improvements in functional outcome than does medication treatment alone."

Xiaofeng Guo, M.D., and Jinguo Zhai, M.D., of Second Xiangya Hospital, Central South University, Hunan, China, and colleagues evaluated this combination of therapies in 1,268 patients with early-stage schizophrenia treated from Jan. 1, 2005, through Oct. 31, 2007. A total of 633 were randomly assigned to receive pharmacotherapy plus a psychosocial intervention involving 48 one-hour group sessions. The intervention included four evidence-based practices: psychoeducation (instruction for families and caregivers about mental illness), family intervention (teaching coping and socializing skills), skills training and cognitive behavioral therapy. The other 635 patients received medication alone.

Rates of treatment discontinuation or change were 32.8 percent in the combined treatment group, compared with 46.8 percent in the medication-only group. The risk of relapse was lower among patients in the combination group, occurring in 14.6 percent of patients in that group and 22.5 percent of patients in the medication-only group.

The combined treatment group also exhibited greater improvements in insight, social functioning, activities of daily living and on four domains of quality of life, and a significantly higher proportion of them were employed or received education. There were no significant differences in either frequency or type of adverse events between the groups.

"Social outcomes reflect how patients live, function in society and perform their various roles (e.g., having a job, going to school or having friends)," the authors write. "Our study showed that a significantly higher proportion of patients receiving combined treatment obtained employment or accessed education. Thus, the findings support the results from previous studies that patients with schizophrenia receiving combined treatment had better outcomes. In particular, integrating a comprehensive therapy with medication treatment in patients with early-stage schizophrenia before the disease becomes chronic and disabling could improve long-term outcomes."


Contact: Debra Kain
JAMA and Archives Journals

Related medicine news :

1. Combining resistance and endurance training best for heart health
2. Gold Standard/Elsevier promotes medication safety and compliance via New MEDcounselor languages
3. Weight-Loss Surgery May Cut Type 2 Diabetes Medication Use
4. 1 in 4 stroke patients stop taking prevention medication within 3 months
5. EEG predicts response to medication for schizophrenia
6. Medications found to cause long term cognitive impairment of aging brain
7. Psychotropic medications can cause birth defects
8. Common Alzheimers medication helps skills necessary for safe driving
9. Non-IV-administered medication just as effective in stopping seizures
10. Publix Pharmacy Now Offers Pill Glide, an Innovative New Way for Children and Adults to Take Vitamins, Supplements and Medications
11. HIRC Research Alert: Health Plans Expected to Increase Adoption of Percent Copays to Manage Specialty Medications
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Brenntag ... exclusive channel partner for the Nutraceutical Specialties products into oral solid dosage in ... immediately. , “We are pleased to announce our expanded distribution agreement with ...
(Date:11/30/2015)... , ... November 30, 2015 , ... An inventor from ... in the womb. "My last baby had high blood pressure due to loud noises," ... to protect their babies from noise pollution as well as radio waves and microwaves." ...
(Date:11/30/2015)... ... November 30, 2015 , ... Since its inception, ... in independent living, assisted living and all other retirement options. Support for issues ... and research remains a top priority. , So it’s no surprise that ...
(Date:11/30/2015)... ... 30, 2015 , ... Sikka Software announced today that they are showcasing the ... to make complex business decisions by providing the tools and information they need to ... with 10 procedures customized by zip code. , The Sikka Software Ecosystem includes ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... the assets of DataTrade Solutions Inc., a Healthcare IT consulting, development and support ... the programming and technical experience available within DataTrade to extend the services currently ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... NEW YORK , November 27, 2015 ... health system is set to go online. The potential ... and processes is vast and far from fully exploited ... access to patient health records, either via mobile tablet ... ) --> ) ...
(Date:11/27/2015)... PHILADELPHIA , Nov. 27, 2015  Lannett ... that it has completed the acquisition of Kremers ... pharmaceuticals subsidiary of global biopharmaceuticals company UCB S.A. ... --> Lannett has acquired KU from UCB ... to certain adjustments, including a customary working capital ...
(Date:11/27/2015)... 2015 ... "2016 Global Tumor Marker Testing Market: ... Sales Segment Forecasts, Innovative Technologies, Instrumentation Review, ... their offering. --> ) ... "2016 Global Tumor Marker Testing Market: Supplier ...
Breaking Medicine Technology: